| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
1 Department of Medicine and 2 Division of Senology, European Institute of Oncology, Milan, Italy; 3 Division of Pathology, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy; and 4 International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute and Frontier Science and Technology Research Foundation, Boston, Massachusetts
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONPATIENTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Experimental Design: In a large volume laboratory using standard immunohistochemical methods, we reviewed the pretreatment biopsies and histologic specimens at final surgery of 399 patients with large or locally advanced breast cancer (cT2-T4, N0–2, M0) who were treated with preoperative chemotherapy. The incidence of pathological complete remission and the incidence of node-negative status at final surgery were assessed with respect to initial pathological and clinical findings. Menopausal status, estrogen receptor status, progesterone receptor status [absent (0% of the cells positive) versus expressed], clinical tumor size, histologic grade, Ki-67, Her-2/neu expression, and type and route of chemotherapy were considered.
Results: High rates of pathological complete remission were associated with absence of estrogen receptor and progesterone receptor expression (P < 0.0001), and grade 3 (P = 0.001). Significant predictors of node-negative status at surgery were absence of estrogen receptor and progesterone receptor expression (P < 0.0001), clinical tumor size <5 cm (P < 0.001), and use of infusional regimens (P = 0.003). The chance of obtaining pathological complete remission or node-negative status for patients with endocrine nonresponsive tumors compared with those having some estrogen receptor or progesterone receptor expression was 4.22 (95% confidence interval, 2.20–8.09, 33.3% versus 7.5%) and 3.47 (95% confidence interval, 2.09–5.76, 42.9% versus 21.7%), respectively. Despite the significantly higher incidence of pathological complete remission and node-negative status achieved by preoperative chemotherapy for patients with estrogen receptor and progesterone receptor absent disease, the disease-free survival was significantly worse for this cohort compared with the low/positive expression cohort (4-year disease-free survival %: 41% versus 74%; hazard ratio 3.22; 95% confidence interval, 2.28–4.54; P < 0.0001).
Conclusions: Response to preoperative chemotherapy is significantly higher for patients with endocrine nonresponsive tumors. New chemotherapy regimens or combinations should be explored in this cohort of patients with poor outcome. For patients with endocrine responsive disease, the role of preoperative endocrine therapies should be studied.
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONPATIENTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Preoperative chemotherapy might be advantageous for patients with breast cancer in several ways in addition to allowing breast conservation surgery in some of the patients. The response to the primary treatment may be used as a prognostic marker, because it was demonstrated to be associated with a longer disease-free survival compared with no response (9) . Not only the response but also the type and degree of response (pathological complete remission) predict overall outcome in terms of disease-free survival (9) . Finally, observed patterns of change for various biological features after exposure to primary treatment might also serve as a surrogate for qualitative and quantitative prediction of response.
Several strategies can be considered to improve results of preoperative chemotherapy. On one hand, the introduction of new drugs in preoperative chemotherapy regimens might provide some benefit as indicated recently in randomized trials (13 , 14) . A second useful strategy to improve knowledge about treatment effects is the early identification of features, which are associated with response or resistance to primary therapy. Identifying these features is a crucial step in the development of the most effective multimodal approaches, using a sequence of local and systemic treatments and identifying cohorts of patients most likely to benefit from preoperative chemotherapy.
To seek information on the predictive value of biological and clinical features we evaluated the course of disease in 399 patients with large operable primary breast cancer who had preoperative diagnosis and surgery performed at the European Institute of Oncology.
|
PATIENTS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONPATIENTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
4,000/mm3; platelets 100,000/mm3, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, 
-GT 
2.5 x upper limit of normal, and bilirubin 3 mg/100 mL. Patients with cardiac disease (congestive heart failure and history of myocardial infarction within the previous 3 months), severe vascular disease, or uncontrolled concomitant infections were excluded. Patients had baseline liver and renal function tests, electrolyte studies, and complete blood count done within 2 weeks of inclusion in the study. Also, bilateral mammography and ultrasound, chest X-ray, abdominal ultrasound, bone scan, serum CA 15.3 determination, and electrocardiography were performed within 2 weeks from the treatment start.
Each patient gave a written informed consent.
Treatment.
Patients were treated with preoperative chemotherapy given in 3-week cycles. After each cycle disease was evaluated by clinical measurement of the two largest diameters. Surgery was planned in patients with clinically progressing disease. After three cycles, patients also had mammography and ultrasound breast examination to assess response. Patients with stable disease received surgery, and those with partial remission or complete remission were candidates to receive three more cycles of therapy, for a maximum of six cycles. The following regimens were used during the conduct of the study: (1) anthracycline containing regimens: ECF: E = Epirubicin 25 mg/m2 i.v., days 1 and 2; C = Cisplatinum 60 mg/m2 i.v. day 1; F = Fluorouracil 200 mg/m2/day as continuous infusion days 1 to 21; AC/EC: A = doxorubicin 60 mg/m2 or E = epirubicin 90 mg/m2 i.v. day 1, C = cyclophosphamide 600 mg/m2 i.v. day 1; (2) Taxane containing regimens: AT/ET: A = doxorubicin 60 mg/m2 or E = epirubicin 90 mg/m2 i.v. day 1, T = taxotere 75 mg/m2 i.v. day 1; (3) Navelbine containing regimens: ViFuP: Vi = Vinorelbine (Navelbine) 20 mg total dose i.v. days 1 and 3; Fu = Fluorouracil 200 mg/m2/day as continuous infusion days 1 to 21; P = (cis)Platinum 60 mg/m2 i.v. day 1; FLN: F = Fluorouracil 350 mg/m2 i.v. days 1 to 3; L = Lederfolin 100 mg/m2 i.v. days 1 to 3; N = navelbine 20 to 25 mg/m2 i.v. days 1 and 3. For regimens including continuous infusion FU, the insertion of a central venous catheter (Dome Port, Bard) was required, and infusion was provided by a Portable Elastomeric Infusion System (Baxter). Patients were instructed to change their own infusion bag every week.
Toxicity and Dose Modifications.
Toxicity was evaluated according to National Cancer Institute of Cancer—Clinical Trials Group criteria by clinical and laboratory evaluations at day 21 of each cycle. If creatinine/blood urea nitrogen was up to 1.5, the upper normal value cisplatin was omitted. In case of constipation, mucositis, or diarrhea (grade >2), the next cycle of chemotherapy was postponed by 1 or 2 weeks until recovery and then administered at 75% of the dose. The treatment was postponed by 1 week if the blood count on day 21 showed a neutrophil count <1,000/mm3 and/or platelet count <100,000 mm3. If on day 28 the neutrophil count was >1,000/mm3 and platelet count >100,000 mm3, the treatment was readministered. Otherwise, treatment was postponed by another week. If after 2 weeks of treatment delay (on day 35) hematologic recovery (neutrophils >1,000 mm3 and platelets >100,000/mm3) was not obtained, treatment was discontinued.
Response Criteria.
Responses were evaluated according to both radiologic (breast ultrasound plus mammography) and clinical evaluation and graded according to standard WHO criteria. Pathological complete remissions were evaluated according to Sataloff et al. criteria (15)
. A pathological complete remission was defined as a total or near total disappearance of the tumor. In particular, absence of invasive cancer or presence of isolated foci of invasive cancer both qualified for pathological complete remission. Axillary lymph nodes were also assessed independent of the primary tumor for the degree of pathological response according to the 5th Tumor-Node-Metastasis Staging System (16)
Pathology and Immunohistochemistry.
This is a single institution study. All of the included patients had pathological evaluation performed at the European Institute of Oncology. The original receptor status determinations, performed before the study conduction, were used. Surgical specimens were extensively sampled for the evaluation of residual tumor after primary chemotherapy. In case of lack of macroscopic evidence of tumor the quadrantectomy specimens were entirely blocked in paraffin and examined histologically, as were the tumor-bearing quadrants of the mastectomies. In the latter cases, the other quadrants were also thoroughly evaluated with the examination of at least three tissue blocks.
Immunostaining experiments for the localization of estrogen and progesterone receptors, Her-2/neu protein, and Ki-67 antigen were performed on consecutive tissue sections of the tru-cut biopsies obtained before primary treatment and from the residual tumor after surgery, as reported previously (17) . The following primary antibodies were used: the monoclonal antibody to estrogen receptor (Dako, at 1:100 dilution), the monoclonal antibody to progesterone receptor (Dako, 1:800), the MIB-1 monoclonal antibody to the Ki-67 antigen (Immunotech, Marseille, France, 1:1200), and the polyclonal antiserum (Dako, 1:3,200) to the Her-2/neu protein.
The immunostained slides were evaluated independently by two of the authors. Only nuclear reactivity was taken into account for estrogen receptor, progesterone receptor, and Ki-67 antigen, whereas only an intense and complete membrane staining >10% of the tumor cells was taken as evidence of Her-2/neu overexpression (3+). The results were recorded as the percentage of immunoreactive cells over at least 2,000 neoplastic cells. The median value of Ki-67 labeling index for the cohort of patients included in the study was used as a cutoff in distinguishing tumors with low (<25%) and high (25%) proliferative fraction. Steroid hormone receptors status was classified as absent (estrogen receptor and progesterone receptor 0% of the cells positive), low (estrogen receptor and/or progesterone receptor 1% <10% of the cells), or positive (estrogen receptor and progesterone receptor 10% of the cells).
Statistical Methods.
The primary endpoints were achieving a pathological complete remission and node-negative status at final surgery. In addition, we evaluated the impact of estrogen receptor and progesterone receptor status and of the degree of response (pathological complete remission and node-negative status) on disease-free survival. We used logistic regression to model the probability of achieving a pathological complete remission first in univariate analyses and then in multiple regression analyses to identify the baseline factors that predicted a pathological complete remission. Similar analyses were performed for modeling nodal status to identify factors that predict node-negative status. Odds ratios, 95% confidence intervals (CI), and Ps were estimated. The Wald test was used to evaluate significance of individual coefficients, and the likelihood ratio test was used to assess a factor with more than two levels (e.g., tumor size). Factors included in the multiple regression analyses were menopausal status, estrogen receptor/progesterone receptor status, pathological grade, Ki-67, Her-2/neu, and treatment regimen. In addition, we explored all of the logistic regression models that included two baseline factors and the two-way interaction between those factors. Associations between categorical variables were assessed by a Fisher’s exact test. Disease-free survival was calculated from the date of first treatment until breast cancer recurrence or a new breast cancer primary or death without recurrence, whichever occurred first. Results are available at a median follow-up of 3.8 years. Assessment of disease-free survival according to estrogen receptor/progesterone receptor status, pathological complete remission status, and nodal status were summarized using the 4-year disease-free survival percentage and the hazard ratio with the respective 95% CI. Cox multiple regression analysis was performed to assess factors predicting disease-free survival. P < 0.05 were considered to be statistically significant. No adjustment was made for performing multiple tests, and all of the probability values were two sided.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONPATIENTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
, the factors that were significantly associated with pathological complete remission were estrogen receptor/progesterone receptor status (P < 0.0001), grade (P < 0.0001), Ki-67 (P = 0.0001), and infusional regimens (P = 0.01). Within the estrogen receptor/progesterone receptor absent cohort, 33.3% achieved a pathological complete remission compared with 7.4% and 7.6% within the estrogen receptor/progesterone receptor low and positive cohorts, respectively. The pathological complete remission percentage for patients with grade 3 tumors was 25.7% compared with 7.6% with grades 1 and 2. For patients with Ki-67 25%, 22.3% achieved a pathological complete remission compared with 8.1% with Ki-67 < 25%. For patients that received infusional therapy, 19.5% had a pathological complete remission versus 10.1% for patients that received no infusional therapy. Differences in pathological complete remission rate according to whether or not an anthracycline was used were not statistically significant.
|
Using a stepwise selection routine at the 0.05 significance level on all factors from the univariate analysis, estrogen receptor/progesterone receptor (P < 0.0001) and grade (P = 0.001) were the two factors that remained statistically significant in the model to predict pathological complete remission. Patients within the estrogen receptor/progesterone receptor absent cohort were 4.22 times (95% CI, 2.20–8.09, P < 0.0001) more likely to achieve a pathological complete remission than patients within the estrogen receptor/progesterone receptor-positive or-low cohort, and patients with grade 3 tumors were 3.36 times (95% CI, 1.62–7.01, P = 0.001) more likely to achieve a pathological complete remission compared with patients with grade 1 or 2 tumors.
A total of 388 (97%) patients had pathological examination of axillary lymph nodes. Of these 388 patients, 28.6% had node-negative disease at the time of final surgery. As shown in Table 2
a significant correlation between node-negative status and pathological complete remission was detected (P < 0.0001). As indicated in Table 1
, the factors that were significantly associated with nodal status were estrogen receptor/progesterone receptor status (P < 0.0001), clinical tumor size (P = 0.001), and use of infusional regimens (P = 0.003).
|
We also evaluated the correlation between Her-2/neu overexpression and response to anthracycline-containing chemotherapy. A slight increased pathological complete remission rate was observed for tumors overexpressing Her-2/neu (33 patients) versus those not overexpressing Her-2/neu (115 patients), although this was not statistically significant (27.3% versus 16.5%, P = 0.21). In regimens not containing anthracyclines, the pathological complete remission rate was similar for Her-2/neu overexpressing tumors (18 patients) and for tumors not overexpressing Her-2/neu (39 patients, 11.1% versus 10.3%, P = 0.99). The interaction between Her-2/neu and chemotherapy regimen was not statistically significant (P = 0.82). Eighty-seven percent of the 336 patients who did not have a pathological complete remission were assessable for estrogen receptor and progesterone receptor at both baseline and final surgery. The changes in estrogen receptor and progesterone receptor category are shown in Table 3
. Estrogen receptor status changed for 9% of the patients (both pre- and post-menopausal), whereas progesterone receptor status changed for 26% of premenopausal patients and 30% of postmenopausal patients. In the present study no significant correlation between modification in the expression of biological features and clinical response was detected, in particular for Ki-67 expression (data not shown).
|
.). Patients who achieve pathological complete remission had a nonstatistically significant worse disease-free survival (57%) than patients who did not achieve pathological complete remission (64%; hazard ratio, 1.29; 95% CI, 0.83–2.00; P = 0.26), possibly due to the higher proportion of receptor absent disease in the pathological complete remission group. Patients who achieve node-negative disease at final surgery had significantly better disease-free survival than patients with node-positive disease (4-year disease-free survival %: 77% versus 60%; hazard ratio, 0.51; 95% CI, 0.31–0.82; P = 0.005). In the Cox multiple regression analyses, the receptor status of the primary tumor was the most significant predictor of disease-free survival.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONPATIENTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Change in the expression of biological features after exposure to the systemic treatment and their possible correlation with clinical response was studied in small cohorts of patients receiving primary chemotherapy. Published trials on patients treated with preoperative chemotherapy or chemoendocrine therapies showed a positive association between Ki-67 reduction with treatment and response (25, 26, 27) . In the present study no significant correlation between modifications of the expression of biological features and clinical response was detected. A slight change in steroid hormone expression, in particular progesterone receptor expression, was observed. A possible explanation for the changes in estrogen receptor/progesterone receptor expression might be related to tissue sampling issues as indicated in a small study from Lee et al. (28) . It is noteworthy, however, that premenopausal-aged women were likely to achieve an endocrine effect with chemotherapy through ovarian function suppression (29) . Also, postmenopausal-aged women may obtain some additional endocrine effect from suppression of adrenals (30) due to cytotoxics and steroids. These endocrine actions of chemotherapy might be the reason for the observed changes in the expression of steroid hormone receptors.
The relationship between steroid hormone receptor expression and response to chemotherapy has received little attention in the past. Two decades have passed since this relationship was debated with the presentation of conflicting reports in the metastatic setting (31 , 32) . Limited data are available on the relationship between number of cells expressing hormone receptors and response to chemotherapy in the preoperative setting. This might be explained by the heterogeneity of examinations, methods, and especially cut-offs used in the various studies. The results of initial immunohistochemical assessment of p53, Her-2/neu, glutathione S-transferase, Ki-67, pS2, and estrogen receptor/progesterone receptor in baseline core biopsy samples of 134 patients from the Bordeaux randomized trial showed that estrogen receptor-negative status (defined at immunohistochemical evaluation as estrogen receptor <10% of the cells) and high Ki-67 were correlated with clinical tumor response (21) . Interestingly, when the analysis was conducted with the dextran-coated charcoal method, less estrogen receptor-positive tumors were detected compared with immunohistochemistry (46% versus 67%), and no significant correlation was detected between response and estrogen receptor status. A more recently published trial showed a significantly higher pathological response rate for estrogen receptor-negative tumors (defined as <10% of the cells) compared with estrogen receptor-positive tumors (25) . The largest experience on hormone receptor expression predicting response in the preoperative setting was published recently and is based on an analysis of the National Surgical Adjuvant breast and Bowel Project B-27 study (13) . Overall, estrogen receptor-negative tumors had higher pathological response rates than did estrogen receptor-positive tumors (16.7% versus 8.3%, respectively, P = 0.001). A test of estrogen receptor status by treatment interaction was not significant (P = 0.69), indicating that estrogen receptor status had little effect on the ability of preoperative docetaxel to improve pathological response. In the trials described above, analyses were performed based on a so-called "receptor-negative grouping," which combines receptor-absent disease with that expressing low receptor levels. In the present study, which represents the largest available analysis conducted by the same team of pathologists on pretreatment biopsies, we demonstrated a different pattern of response to chemotherapy for endocrine nonresponsive disease (defined as steroid hormone receptor absent tumor). Some clinical studies (33) and gene expression profiling (34 , 35) already provide empirical data that receptor-absent breast cancer is a distinct entity from that with even low levels of receptor expression.
In the present study both the pathological complete remission rate and the frequency of node-negative status at final surgery were significantly higher after preoperative chemotherapy for patients whose tumors did not express estrogen receptor and progesterone receptor, compared with the receptor-expressing cohort. This emphasizes the chemoresponsiveness of tumors that do not express any estrogen receptor or progesterone receptor. Despite the high pathological complete remission rate and node-negative status, the disease-free survival at 3.8 years of median follow-up was significantly worse for the receptor-absent compared with the receptor-present groups. The responsiveness of tumors expressing some receptors to endocrine therapies (e.g., ovarian function suppression, tamoxifen, and aromatase inhibitors) might explain the different outcome observed. In fact, after surgery patients with endocrine unresponsive disease generally did not received additional systemic therapy, whereas those with endocrine-responsive disease received additional endocrine treatment postoperatively. These findings provide substantial additional evidence to support the hypothesis that steroid hormone receptor status of the primary tumor defines distinct biological entities that require a differentiated approach to treatment and clinical trial investigation. Separate analyses according to steroid hormone receptor status must be prospectively planned for future clinical trials and conducted for current and past studies whether or not these were prospectively included in the protocol.
The efficacy of systemic therapy for early breast cancer depends on features of the treatment as well as the tumor and the patient. The introduction of taxanes provided encouraging results in recent trials in the preoperative setting. Smith et al. (14)
reported higher pathological complete remission rate on patients with large or locally advanced breast cancer who, after four cycles of cyclophosphamide, doxorubicin, vincristine, and prednisolone, received four courses of taxotere versus four additional courses of cyclophosphamide, doxorubicin, vincristine, and prednisolone (34% versus 16%, respectively, P = 0.04). In the National Surgical Adjuvant breast and Bowel Project B-27 the addition of 4 cycles of taxotere after 4 cycles of AC significantly improved pathological complete remission from 13.7% to 26.1% (13)
. Whereas no information on response and endocrine responsiveness is available for the former trial, in the National Surgical Adjuvant breast and Bowel Project trial the results across all of the age groups are not informative concerning chemosensitivity of the use of taxanes for estrogen receptor-positive disease. Fifty-six percent of the patients were 49 years old, and 30% were in the 50 to 59 age group. It is likely that more than two thirds of the patients were premenopausal, and differential endocrine effects of the chemotherapy regimens contributed to the finding in the estrogen receptor-positive cohort. Furthermore, because tamoxifen was given concurrently with chemotherapy, the tamoxifen duration was either 24 weeks or 12 weeks according to treatment assignment making comparisons for the receptor-positive cohort quite problematic. In addition, mixing estrogen receptor absent and estrogen receptor-low tumors together in the category labeled as estrogen receptor-negative attenuates the chemosensitivity that might have been observed in the truly endocrine unresponsive cohort.
In conclusion, the present study indicates the importance of preoperative chemotherapy for patients with estrogen receptor- and progesterone receptor-absent tumors, as well as the poor outcome in terms of disease-free survival for this patient population. Additional studies using database analyses or prospective trials are required to confirm the value and limitations of primary chemotherapy in endocrine nonresponsive tumors. If confirmed, future selection of preoperative treatment should be based on tumor characteristics such as estrogen receptor and progesterone receptor status, and the current practice of many laboratories to report receptor status as merely positive or negative should change to a more quantitative reporting of routine receptor determinations to identify the estrogen receptor and progesterone receptor-absent cohort.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Requests for reprints: Marco Colleoni, Department of Medicine, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan Italy. Phone: 39-02-57489439; Fax: 39-02-574829212; E-mail: marco.colleoni{at}ieo.it
Received 2/26/04; revised 6/15/04; accepted 7/ 1/04.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONPATIENTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  G. Frasci, P. Comella, M. Rinaldo, G. Iodice, M. Di Bonito, M. D'Aiuto, A. Petrillo, S. Lastoria, C. Siani, G. Comella, et al. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer Ann. Onc., July 1, 2009; 20(7): 1185 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. Barrios, C. Sampaio, J. Vinholes, and R. Caponero What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer? Ann. Onc., July 1, 2009; 20(7): 1157 - 1162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Guarneri, F. Piacentini, G. Ficarra, A. Frassoldati, R. D'Amico, S. Giovannelli, A. Maiorana, G. Jovic, and P. Conte A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy Ann. Onc., July 1, 2009; 20(7): 1193 - 1198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tanei, K. Morimoto, K. Shimazu, S. J. Kim, Y. Tanji, T. Taguchi, Y. Tamaki, and S. Noguchi Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers Clin. Cancer Res., June 15, 2009; 15(12): 4234 - 4241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. MIGLIETTA, P. VANELLA, L. CANOBBIO, M. A. PARODI, P. GUGLIELMINI, and F. BOCCARDO Clinical and Pathological Response to Primary Chemotherapy in Patients with Locally Advanced Breast Cancer Grouped According to Hormonal Receptors, Her2 Status, Grading and Ki-67 Proliferation Index Anticancer Res, May 1, 2009; 29(5): 1621 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. HORIGUCHI, T. OYAMA, Y. KOIBUCHI, T. YOKOE, D. TAKATA, F. IKEDA, H. NAGAOKA, N. ROKUTANDA, R. NAGAOKA, Y. ISHIKAWA, et al. Neoadjuvant Weekly Paclitaxel with and without Trastuzumab in Locally Advanced or Metastatic Breast Cancer Anticancer Res, February 1, 2009; 29(2): 517 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dowsett and A. K. Dunbier Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer Clin. Cancer Res., December 15, 2008; 14(24): 8019 - 8026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Berruti, M. P. Brizzi, D. Generali, M. Ardine, L. Dogliotti, P. Bruzzi, and A. Bottini Presurgical Systemic Treatment of Nonmetastatic Breast Cancer: Facts and Open Questions Oncologist, November 1, 2008; 13(11): 1137 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-S. Huang, S.-H. Kuo, H.-C. Lien, S.-Y. Yang, S.-L. You, C.-Y. Shen, C.-H. Lin, Y.-S. Lu, and K.-J. Chang The CYP19 TTTA Repeat Polymorphism Is Related to the Prognosis of Premenopausal Stage I-II and Operable Stage III Breast Cancers Oncologist, July 1, 2008; 13(7): 751 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Gluz, U. A. Nitz, N. Harbeck, E. Ting, R. Kates, A. Herr, W. Lindemann, C. Jackisch, W. E. Berdel, H. Kirchner, et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial Ann. Onc., May 1, 2008; 19(5): 861 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Colleoni, G. Viale, D. Zahrieh, L. Bottiglieri, R. D. Gelber, P. Veronesi, A. Balduzzi, R. Torrisi, A. Luini, M. Intra, et al. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy Ann. Onc., March 1, 2008; 19(3): 465 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-C. Chen, H.-K. Chang, Y.-C. Lin, S. Hsueh, Y.-C. Cheung, W.-M. Leung, C.-S. Tsai, Y.-F. Lo, H.-P. Tsai, S.-C. Shen, et al. High Pathologic Complete Response in HER 2-positive Locally Advanced Breast Cancer after Primary Systemic Chemotherapy with Weekly Docetaxel and Epirubicin Jpn. J. Clin. Oncol., February 12, 2008; (2008) hym172v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Rastogi, S. J. Anderson, H. D. Bear, C. E. Geyer, M. S. Kahlenberg, A. Robidoux, R. G. Margolese, J. L. Hoehn, V. G. Vogel, S. R. Dakhil, et al. Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J. Clin. Oncol., February 10, 2008; 26(5): 778 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kaufmann, G. von Minckwitz, H. D. Bear, A. Buzdar, P. McGale, H. Bonnefoi, M. Colleoni, C. Denkert, W. Eiermann, R. Jackesz, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006 Ann. Onc., December 1, 2007; 18(12): 1927 - 1934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The International Breast Cancer Study Group Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93 Ann. Onc., July 1, 2007; 18(7): 1177 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Veronesi, P. Maisonneuve, N. Rotmensz, B. Bonanni, P. Boyle, G. Viale, A. Costa, V. Sacchini, R. Travaglini, G. D'Aiuto, et al. Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy J Natl Cancer Inst, May 2, 2007; 99(9): 727 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Paik, G. Tang, S. Shak, C. Kim, J. Baker, W. Kim, M. Cronin, F. L. Baehner, D. Watson, J. Bryant, et al. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer J. Clin. Oncol., August 10, 2006; 24(23): 3726 - 3734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bottini, D. Generali, M. P. Brizzi, S. B. Fox, A. Bersiga, S. Bonardi, G. Allevi, S. Aguggini, G. Bodini, M. Milani, et al. Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients J. Clin. Oncol., August 1, 2006; 24(22): 3623 - 3628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Sachelarie, M. L. Grossbard, M. Chadha, S. Feldman, M. Ghesani, and R. H. Blum Primary Systemic Therapy of Breast Cancer Oncologist, June 1, 2006; 11(6): 574 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Bear, S. Anderson, R. E. Smith, C. E. Geyer Jr, E. P. Mamounas, B. Fisher, A. M. Brown, A. Robidoux, R. Margolese, M. S. Kahlenberg, et al. Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J. Clin. Oncol., May 1, 2006; 24(13): 2019 - 2027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Berry, C. Cirrincione, I. C. Henderson, M. L. Citron, D. R. Budman, L. J. Goldstein, S. Martino, E. A. Perez, H. B. Muss, L. Norton, et al. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer JAMA, April 12, 2006; 295(14): 1658 - 1667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Guarneri, K. Broglio, S.-W. Kau, M. Cristofanilli, A. U. Buzdar, V. Valero, T. Buchholz, F. Meric, L. Middleton, G. N. Hortobagyi, et al. Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other Factors J. Clin. Oncol., March 1, 2006; 24(7): 1037 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Colleoni, L. Orlando, G. Sanna, A. Rocca, P. Maisonneuve, G. Peruzzotti, R. Ghisini, M. T. Sandri, L. Zorzino, F. Nole, et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects Ann. Onc., February 1, 2006; 17(2): 232 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, B. Thurlimann, H.-J. Senn, and and Panel Members Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005 Ann. Onc., October 1, 2005; 16(10): 1569 - 1583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Demicheli, R. Miceli, A. Moliterni, M. Zambetti, W. J. M. Hrushesky, M. W. Retsky, P. Valagussa, and G. Bonadonna Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process Ann. Onc., September 1, 2005; 16(9): 1449 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bonnefoi 'Small' randomised neo-adjuvant chemotherapy trials in breast cancer reporting on pathological response: more harm than good? Ann. Onc., September 1, 2005; 16(9): 1407 - 1410. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
